Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas

被引:3
|
作者
Tang, Guilin [1 ]
Li, Shaoying [1 ]
Toruner, Gokce A. [1 ]
Jain, Preetesh [2 ]
Tang, Zhenya [1 ]
Hu, Shimin [1 ]
Xu, Jie [1 ]
Cheng, Joanne [1 ]
Robinson, Melissa [1 ]
Vega, Francisco [1 ]
Medeiros, L. Jeffrey [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
关键词
Aggressive B-cell lymphoma; Unbalanced MYC rearrangement; 5 ' MYC gain; deletion; 3 ' MYC gain; DOUBLE-HIT LYMPHOMA; RITUXIMAB-CHOP; DLBCL PATIENTS; MYC; REARRANGEMENTS; CLASSIFICATION; TRANSLOCATIONS; BREAKPOINTS; EXPRESSION; SURVIVAL;
D O I
10.1016/j.cancergen.2022.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FISH analysis using MYC break-apart probes is a widely used technique to assess for MYC rearrangement (MYC-R). Occasionally, FISH results in atypical signal patterns, such as gain or loss of 5'MYC or 3'MYC. The clinical impact and/or relationship of these atypical signal patterns to MYC-R are unknown. In this study, we assessed 35 patients who had aggressive B-cell lymphomas and exhibited atypical FISH signal pat-terns: 3'MYC deletion ( n = 16) or 3'MYC deletion plus 5'MYC amplification ( n = 5), 5'MYC gain ( n = 10), 5'MYC deletion ( n = 3), and 3'MYC gain ( n = 1). For comparison, we also included 9 patients who showed an unbalanced MYC-R. Patients with 5'MYC gain showed MYC expression and were often refractory to chemotherapy ( n = 7) or had early relapse ( n = 2). By contrast, lymphomas with 3'MYC deletion were negative or had low expression of MYC (16 of 18), and patients often responded to chemotherapy (16 of 19). The median event-free survival was 24, 6, and 4 months for patients with 3'MYC deletion, 5'MYC gain and unbalanced MYC-R, respectively ( p = 0.0048). We conclude that 5'MYC gain is associated with MYC expression and a poorer prognosis and likely represents an unbalanced MYC-R. By contrast, 3'MYC dele-tions are not associated with MYC expression or a poorer prognosis and this finding may be unrelated to MYC-R. (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [41] Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond
    Hsi, Eric D.
    LANCET HAEMATOLOGY, 2018, 5 (12): : E600 - E601
  • [42] LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas
    Colomo, Luis
    Vazquez, Ivonne
    Papaleo, Natalia
    Espinet, Blanca
    Ferrer, Anna
    Franco, Catalina
    Comerma, Laura
    Hernandez, Silvia
    Calvo, Xavier
    Salar, Antonio
    Climent, Fina
    Luis Mate, Jose
    Forcada, Pilar
    Mozos, Anna
    Nonell, Lara
    Martinez, Antonio
    Carrio, Anna
    Costa, Dolors
    Dlouhy, Ivan
    Salaverria, Itziar
    Ignacio Martin-Subero, Jose
    Lopez-Guillermo, Armando
    Valera, Alexandra
    Campo, Elias
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (07) : 877 - 886
  • [43] A targeted molecular classifier of MYC activity and BCL-2 expression in aggressive B-cell lymphomas, designed for clinical practice
    Carey, Christopher D.
    Gusenleitner, Daniel
    Chapuy, Bjoern
    Sun, Heather
    Ligon, Azra
    Kovach, Alexandra E.
    Le, Long P.
    Sohani, Aliyah R.
    Shipp, Margaret
    Monti, Stefano
    Rodig, Scott J.
    CANCER RESEARCH, 2014, 74 (19)
  • [44] Aggressive B-Cell Lymphomas With Translocations Involving BCL6 and MYC Have Distinct Clinical-Pathologic Characteristics
    Turakhia, Samir K.
    Hill, Brian T.
    Dufresne, Scott D.
    Nakashima, Megan O.
    Cotta, Claudiu V.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (03) : 339 - 346
  • [45] Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis
    Lynnhtun, Kyaw
    Renthawa, Jasveen
    Varikatt, Winny
    PATHOLOGY, 2014, 46 (03) : 211 - 215
  • [46] When and how to test for C-MYC in aggressive B cell lymphomas
    Sylvia Hoeller
    Alexandar Tzankov
    Frank Stenner
    Stephan Dirnhofer
    Journal of Hematopathology, 2015, 8 : 13 - 20
  • [47] When and how to test for C-MYC in aggressive B cell lymphomas
    Hoeller, Sylvia
    Tzankov, Alexandar
    Stenner, Frank
    Dirnhofer, Stephan
    JOURNAL OF HEMATOPATHOLOGY, 2015, 8 (01) : 13 - 20
  • [48] Immunohistochemical and Genetic Evaluation of MYC Translocation Positive Aggressive B Cell Lymphomas
    Grimm, K. E.
    Agrawal, R.
    Weiss, L.
    O'Malley, D. P.
    LABORATORY INVESTIGATION, 2013, 93 : 330A - 330A
  • [49] Immunohistochemical and Genetic Evaluation of MYC Translocation Positive Aggressive B Cell Lymphomas
    Grimm, K. E.
    Agrawal, R.
    Weiss, L.
    O'Malley, D. P.
    MODERN PATHOLOGY, 2013, 26 : 330A - 330A
  • [50] Chemoprevention of B-Cell Lymphomas by Inhibition of the Myc Target Spermidine Synthase
    Forshell, TachaZi Plym
    Rimpi, Sara
    Nilsson, Jonas A.
    CANCER PREVENTION RESEARCH, 2010, 3 (02) : 140 - 147